# BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

> **NCT03914742** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 67 (actual)

## Conditions studied

- IDH1 Mutation
- IDH2 Mutation
- Recurrent Glioblastoma
- Recurrent WHO Grade II Glioma
- Recurrent WHO Grade III Glioma

## Interventions

- **DRUG:** PARP Inhibitor BGB-290
- **DRUG:** Temozolomide
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT03914742
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-16
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03914742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03914742, "BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03914742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*